PHARMAC is seeking feedback on a proposal to widen access to tocilizumab in DHB hospitals from 1 January 2015 for use in patients with rheumatoid arthritis who have received inadequate benefit from both a tumour necrosis factor (TNF)-alpha inhibitor (adalimumab or etanercept) and rituximab.

For more details, go to: http://www.pharmac.health.nz/assets/consultation-2014-11-13-tocilizumab.pdf